vs

Side-by-side financial comparison of STANDARD BIOTOOLS INC. (LAB) and Open Lending Corp (LPRO). Click either name above to swap in a different company.

STANDARD BIOTOOLS INC. is the larger business by last-quarter revenue ($19.6M vs $19.3M, roughly 1.0× Open Lending Corp). On growth, Open Lending Corp posted the faster year-over-year revenue change (134.0% vs -11.5%). Open Lending Corp produced more free cash flow last quarter ($-3.3M vs $-23.1M). Over the past eight quarters, STANDARD BIOTOOLS INC.'s revenue compounded faster (-12.2% CAGR vs -20.7%).

Standard BioTools Inc., previously known as Fluidigm Corp., is an American life science tools company that offers analytical mass cytometry systems for flow cytometry and tissue imaging, along with associated assays and reagents, as well as an automated genomic analysis instrument and a variety of microfluidic arrays, or integrated fluidic circuits (IFCs), and consumables with fully kitted reagents. Custom assays and services are available with all systems and applications.

Open Library is an online project intended to create "one web page for every book ever published". Created by Aaron Swartz, Brewster Kahle, Alexis Rossi, Anand Chitipothu, and Rebecca Hargrave Malamud, Open Library is a project of the Internet Archive, a nonprofit organization. It has been funded in part by grants from the California State Library and the Kahle/Austin Foundation. Open Library provides online digital copies in multiple formats, created from images of many public domain, out-of...

LAB vs LPRO — Head-to-Head

Bigger by revenue
LAB
LAB
1.0× larger
LAB
$19.6M
$19.3M
LPRO
Growing faster (revenue YoY)
LPRO
LPRO
+145.5% gap
LPRO
134.0%
-11.5%
LAB
More free cash flow
LPRO
LPRO
$19.8M more FCF
LPRO
$-3.3M
$-23.1M
LAB
Faster 2-yr revenue CAGR
LAB
LAB
Annualised
LAB
-12.2%
-20.7%
LPRO

Income Statement — Q3 FY2025 vs Q4 FY2025

Metric
LAB
LAB
LPRO
LPRO
Revenue
$19.6M
$19.3M
Net Profit
$-34.7M
Gross Margin
48.5%
76.0%
Operating Margin
-168.5%
3.9%
Net Margin
-177.4%
Revenue YoY
-11.5%
134.0%
Net Profit YoY
-28.8%
EPS (diluted)
$-0.09
$-0.00

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
LAB
LAB
LPRO
LPRO
Q4 25
$19.3M
Q3 25
$19.6M
$24.2M
Q2 25
$21.8M
$25.3M
Q1 25
$40.8M
$24.4M
Q4 24
$-56.9M
Q3 24
$22.1M
$23.5M
Q2 24
$22.5M
$26.7M
Q1 24
$45.5M
$30.7M
Net Profit
LAB
LAB
LPRO
LPRO
Q4 25
Q3 25
$-34.7M
$-7.6M
Q2 25
$-33.5M
$1.0M
Q1 25
$-26.0M
$617.0K
Q4 24
Q3 24
$-26.9M
$1.4M
Q2 24
$-45.7M
$2.9M
Q1 24
$-32.2M
$5.1M
Gross Margin
LAB
LAB
LPRO
LPRO
Q4 25
76.0%
Q3 25
48.5%
78.0%
Q2 25
48.8%
78.2%
Q1 25
48.4%
75.1%
Q4 24
111.0%
Q3 24
54.9%
73.9%
Q2 24
46.1%
78.6%
Q1 24
53.1%
81.3%
Operating Margin
LAB
LAB
LPRO
LPRO
Q4 25
3.9%
Q3 25
-168.5%
-31.9%
Q2 25
-118.1%
4.6%
Q1 25
-80.8%
3.1%
Q4 24
138.0%
Q3 24
-120.9%
7.9%
Q2 24
-134.5%
14.9%
Q1 24
-132.2%
23.8%
Net Margin
LAB
LAB
LPRO
LPRO
Q4 25
Q3 25
-177.4%
-31.3%
Q2 25
-153.7%
4.1%
Q1 25
-63.8%
2.5%
Q4 24
Q3 24
-122.0%
6.1%
Q2 24
-203.3%
10.9%
Q1 24
-70.6%
16.5%
EPS (diluted)
LAB
LAB
LPRO
LPRO
Q4 25
$-0.00
Q3 25
$-0.09
$-0.06
Q2 25
$-0.09
$0.01
Q1 25
$-0.07
$0.01
Q4 24
$-1.20
Q3 24
$-0.07
$0.01
Q2 24
$-0.12
$0.02
Q1 24
$-0.27
$0.04

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
LAB
LAB
LPRO
LPRO
Cash + ST InvestmentsLiquidity on hand
$129.4M
$176.6M
Total DebtLower is stronger
$84.8M
Stockholders' EquityBook value
$399.7M
$75.0M
Total Assets
$539.6M
$236.7M
Debt / EquityLower = less leverage
1.13×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
LAB
LAB
LPRO
LPRO
Q4 25
$176.6M
Q3 25
$129.4M
$222.1M
Q2 25
$158.6M
$230.7M
Q1 25
$150.9M
$236.2M
Q4 24
$243.2M
Q3 24
$210.6M
$250.2M
Q2 24
$269.8M
$248.0M
Q1 24
$287.1M
$247.0M
Total Debt
LAB
LAB
LPRO
LPRO
Q4 25
$84.8M
Q3 25
$134.4M
Q2 25
$136.1M
Q1 25
$137.9M
Q4 24
$139.7M
Q3 24
$55.2M
$141.5M
Q2 24
$55.1M
$143.3M
Q1 24
$55.0M
$143.2M
Stockholders' Equity
LAB
LAB
LPRO
LPRO
Q4 25
$75.0M
Q3 25
$399.7M
$72.8M
Q2 25
$424.5M
$78.9M
Q1 25
$454.6M
$79.8M
Q4 24
$78.1M
Q3 24
$489.3M
$220.5M
Q2 24
$510.3M
$216.8M
Q1 24
$577.3M
$211.5M
Total Assets
LAB
LAB
LPRO
LPRO
Q4 25
$236.7M
Q3 25
$539.6M
$287.7M
Q2 25
$557.0M
$296.7M
Q1 25
$579.6M
$304.2M
Q4 24
$296.4M
Q3 24
$681.5M
$395.7M
Q2 24
$708.7M
$382.8M
Q1 24
$777.7M
$380.6M
Debt / Equity
LAB
LAB
LPRO
LPRO
Q4 25
1.13×
Q3 25
1.84×
Q2 25
1.72×
Q1 25
1.73×
Q4 24
1.79×
Q3 24
0.11×
0.64×
Q2 24
0.11×
0.66×
Q1 24
0.10×
0.68×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
LAB
LAB
LPRO
LPRO
Operating Cash FlowLast quarter
$-22.2M
$-3.2M
Free Cash FlowOCF − Capex
$-23.1M
$-3.3M
FCF MarginFCF / Revenue
-118.1%
-16.8%
Capex IntensityCapex / Revenue
4.5%
0.3%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-111.1M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
LAB
LAB
LPRO
LPRO
Q4 25
$-3.2M
Q3 25
$-22.2M
$-5.7M
Q2 25
$-20.7M
$848.0K
Q1 25
$-30.3M
$-3.8M
Q4 24
$17.6M
Q3 24
$-27.9M
$11.4M
Q2 24
$-39.0M
$-1.4M
Q1 24
$-62.5M
$11.0M
Free Cash Flow
LAB
LAB
LPRO
LPRO
Q4 25
$-3.3M
Q3 25
$-23.1M
Q2 25
$-22.6M
$837.0K
Q1 25
$-35.3M
$-3.9M
Q4 24
$17.4M
Q3 24
$-30.1M
$11.3M
Q2 24
$-41.0M
$-1.5M
Q1 24
$-63.3M
FCF Margin
LAB
LAB
LPRO
LPRO
Q4 25
-16.8%
Q3 25
-118.1%
Q2 25
-103.6%
3.3%
Q1 25
-86.6%
-15.9%
Q4 24
-30.6%
Q3 24
-136.4%
48.0%
Q2 24
-182.2%
-5.5%
Q1 24
-138.9%
Capex Intensity
LAB
LAB
LPRO
LPRO
Q4 25
0.3%
Q3 25
4.5%
0.0%
Q2 25
8.7%
0.0%
Q1 25
12.4%
0.2%
Q4 24
-0.3%
Q3 24
10.2%
0.5%
Q2 24
8.6%
0.2%
Q1 24
1.7%
0.0%
Cash Conversion
LAB
LAB
LPRO
LPRO
Q4 25
Q3 25
Q2 25
0.82×
Q1 25
-6.22×
Q4 24
Q3 24
7.92×
Q2 24
-0.48×
Q1 24
2.16×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

LAB
LAB

Consumables$8.7M45%
Services And Other Revenue$5.8M29%
Instruments$5.1M26%

LPRO
LPRO

Segment breakdown not available.

Related Comparisons